Neumora Therapeutics (NMRA) News Today $1.62 -0.04 (-2.41%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Average Price Target from AnalystsSeptember 12 at 2:33 AM | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsSeptember 11 at 5:13 AM | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 26.3% in AugustSeptember 10 at 6:40 PM | marketbeat.comNuveen LLC Takes $221,000 Position in Neumora Therapeutics, Inc. $NMRASeptember 8, 2025 | marketbeat.comGraham Capital Management L.P. Has $1.16 Million Holdings in Neumora Therapeutics, Inc. $NMRASeptember 6, 2025 | marketbeat.comNeumora Therapeutics to Participate in Upcoming Conferences in SeptemberSeptember 2, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Sells 2,899,770 Shares of Neumora Therapeutics, Inc. $NMRAAugust 27, 2025 | marketbeat.comNeumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861August 20, 2025 | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsAugust 16, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by XTX Topco LtdAugust 14, 2025 | marketbeat.comFederated Hermes Inc. Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)August 11, 2025 | marketbeat.comQ3 EPS Estimate for Neumora Therapeutics Boosted by AnalystAugust 11, 2025 | marketbeat.comWilliam Blair Issues Positive Outlook for NMRA EarningsAugust 11, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215August 7, 2025 | tipranks.comNeumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215August 7, 2025 | msn.comNeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNeumora Therapeutics Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)August 6, 2025 | msn.comNeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comNeumora Therapeutics (NMRA) Expected to Announce Earnings on WednesdayJuly 30, 2025 | marketbeat.comMizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingJuly 30, 2025 | msn.comNeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 23, 2025 | globenewswire.comMizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform RatingJuly 20, 2025 | finance.yahoo.comNeumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at MizuhoJuly 16, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861July 10, 2025 | finanznachrichten.deNeumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861July 9, 2025 | globenewswire.comWith 43% ownership, Neumora Therapeutics, Inc. (NASDAQ:NMRA) has piqued the interest of institutional investorsJuly 2, 2025 | finance.yahoo.comLunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA)June 29, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by AnalystsJune 26, 2025 | marketbeat.comNeumora Therapeutics Inc News (NMRA) - Investing.comJune 24, 2025 | investing.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 27, 2025 | globenewswire.comNeumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug developmentMay 24, 2025 | uk.investing.comSoftbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 18, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of NMRA Q2 EarningsMay 17, 2025 | marketbeat.comQ2 EPS Forecast for Neumora Therapeutics Raised by AnalystMay 17, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MDMay 17, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPSMay 14, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 14, 2025 | prnewswire.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deNeumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...May 13, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comNeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comWill Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?May 11, 2025 | finance.yahoo.comSchonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 5, 2025 | marketbeat.comNeumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comNeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025April 28, 2025 | globenewswire.comCapital International Investors Raises Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)April 23, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmApril 16, 2025 | investing.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by AnalystsApril 14, 2025 | marketbeat.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼1.410.93▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼68▲NMRA Articles Average Week Get the Latest News and Ratings for NMRA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Neumora Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Upstream Bio News Today Sionna Therapeutics News Today Oric Pharmaceuticals News Today Pharming Group News Today Spyre Therapeutics News Today ARS Pharmaceuticals News Today Praxis Precision Medicines News Today uniQure News Today atai Life Sciences News Today Cronos Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
